Sensus Healthcare introduces Silk™ laser hair removal

0

BOCA RATON, Fla., Oct. 20, 2022 (GLOBE NEWSWIRE) — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncology and non-oncology conditions, announces the launch of its Silk™ by Sensus wearable hair removal system with mixed wavelengths at the Fall Clinical Dermatology Conference, to be held October 20-23 in Las Vegas.

Silk by Sensus features a truly portable 2000W diode laser, lightweight handpiece, super cool cooling tip and high repetition rates. The ability to mix wavelengths while emitting light vertically to the skin increases efficiency by maintaining laser density in the selected area resulting in deeper, better penetration and more energy distribution homogeneous. Above all, the laser is sensitive to all skin types, which makes laser hair removal accessible to everyone.

Commenting on the launch, Joe Sardano, President and CEO of Sensus Healthcare, said, “We are excited to showcase the latest cutting-edge aesthetic laser technology at the Fall Clinical Dermatology Conference, which brings together thousands of practitioners dedicated to the advancing skin health and providing the latest and greatest technology to their patients. With its unique combination of optimized energy delivery, versatility, speed, comfort and efficiency, we believe Silk by Sensus sets a new standard in laser hair removal.

Silk by Sensus allows complete hair removal on any part of the body. There are no disposables associated with the laser, which improves affordability for physicians and patients, and there is no need for a heavy secondary cooling unit. Silk by Sensus is offered in two modes:

  • 810, which uses the standard 810nm single wavelength for hair removal on most skin and hair types
  • BLEND, which uses a combination of four clinically proven wavelengths (755, 810, 940 and 1064 nm) to achieve seamless coverage across the spectrum of skin and hair types

Both modes are now available nationwide. Interested customers should call 561-922-5808 or email [email protected].

About the Fall Clinic

The Annual Fall Conference on Clinical Dermatology® is a four-day accredited CME course that provides a comprehensive update on the diagnosis and treatment of a variety of conditions related to medical, surgical, and cosmetic dermatology.

About Sensus Health

Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally invasive, and cost-effective treatments for oncology and non-oncology conditions. Sensus offers its proprietary low-energy X-ray technology known as Superficial Radiation Therapy (SRT), which is the culmination of over a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100SRT-100+ and SRT-100 Vision systems. With its innovative medical device product portfolio, including aesthetic lasers and its needle-free transdermal infusion system, Sensus offers breakthrough treatment options to improve the quality of life of patients around the world. For more information, visit www.sensushealthcare.com.

Forward-looking statements

This press release contains statements that are or may be deemed to be “forward-looking statements”. In some cases, these statements can be identified by the use of forward-looking terminology such as “believes”, “estimates”, “anticipates”, “expects”, “plans”, “intends”. , “may”, “could”, “could”, “will”, “should”, “approximately”, “potential” or negative or other variations of these terms or comparable terminology, although not all forward-looking statements contain not those words.

Forward-looking statements involve risks and uncertainties because they relate to events, developments and circumstances relating to Sensus, our industry and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timeframes. or to a greater or lesser degree than expected. Although we believe we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development industry conditions in which we operate may differ materially from the forward-looking statements contained in this press release due to, among other things, the following factors: the continuation and severity of the COVID-19 pandemic, including its impact on sales and marketing; our ability to achieve profitability; our ability to obtain and retain the intellectual property necessary to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; the level and availability of government and/or third-party payer reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; regulatory requirements applicable to us and our competitors; our ability to effectively manage our manufacturing processes and costs; risks arising from our international operations; laws, regulations or other government action that affect our products, taxes, international trade regulations or other aspects of our business; the concentration of our customers in the United States and China, including the concentration of sales to a particular customer in the United States; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q.

In addition, even if future events, developments and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements we make in this press release speak only as of the date of this statement, and we assume no obligation to update such statements to reflect events or circumstances after the date of this release. release, except as may be required by applicable law. You should carefully read our “Introductory Note Regarding Forward-Looking Information” and the factors described in the “Risk Factors” section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our activities.

Contact:
LHA Investor Relations
Kim Sutton-Golodetz
212-838-3777
[email protected]

# # #

Share.

Comments are closed.